Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

pan-EGFR inhibitor

DRUG CLASS:

pan-EGFR inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

poziotinib (17)

poziotinib (17)

›

HER-2 exon 20 mutation	Non Small Cell Lung Cancer	HER-2 exon 20 mutation	Non Small Cell Lung Cancer	poziotinib Sensitive: B - Late Trials poziotinib Sensitive : B	poziotinib Sensitive: B - Late Trials poziotinib Sensitive : B
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2
HER-2 YVMA	Lung Cancer	HER-2 YVMA	Lung Cancer	HER2-targeted CAR-T immunotherapy + poziotinib Sensitive: C2 – Inclusion Criteria HER2-targeted CAR-T immunotherapy + poziotinib Sensitive : C2	HER2-targeted CAR-T immunotherapy + poziotinib Sensitive: C2 – Inclusion Criteria HER2-targeted CAR-T immunotherapy + poziotinib Sensitive : C2
HER-2 positive	Non Small Cell Lung Cancer	HER-2 positive	Non Small Cell Lung Cancer	poziotinib Sensitive: C3 – Early Trials poziotinib Sensitive : C3	poziotinib Sensitive: C3 – Early Trials poziotinib Sensitive : C3
HER-2 G778_P780dup	Non Small Cell Lung Cancer	HER-2 G778_P780dup	Non Small Cell Lung Cancer	poziotinib Sensitive: C3 – Early Trials poziotinib Sensitive : C3	poziotinib Sensitive: C3 – Early Trials poziotinib Sensitive : C3
EGFR L858R + EGFR M766Q	Lung Adenocarcinoma	EGFR L858R + EGFR M766Q	Lung Adenocarcinoma	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D
HER-2 V777L + EGFR L858R	Lung Cancer	HER-2 V777L + EGFR L858R	Lung Cancer	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D
HER-2 exon 20 insertion	Lung Adenocarcinoma	HER-2 exon 20 insertion	Lung Adenocarcinoma	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D
ABCB1 overexpression	Ovarian Cancer	ABCB1 overexpression	Ovarian Cancer	lapatinib + poziotinib Sensitive: D – Preclinical lapatinib + poziotinib Sensitive : D	lapatinib + poziotinib Sensitive: D – Preclinical lapatinib + poziotinib Sensitive : D
HER-2 G778_P780dup	Breast Cancer	HER-2 G778_P780dup	Breast Cancer	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D
HER-2 L755S	Breast Cancer	HER-2 L755S	Breast Cancer	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D
HER-2 T862A + HER-2 L755S	Breast Cancer	HER-2 T862A + HER-2 L755S	Breast Cancer	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D